FDA clears Pfizer, Moderna Covid booster shots for all adults
Any adult may now receive a Moderna or Pfizer booster regardless of the which FDA-authorized vaccination course they received previously.
Any adult may now receive a Moderna or Pfizer booster regardless of the which FDA-authorized vaccination course they received previously.
Any adult may now receive a Moderna or Pfizer booster regardless of the which FDA-authorized vaccination course they received previously.
The agency’s effort to decide which e-cigarettes can stay on the market could force it to confront the menthol question much sooner.
The agency’s effort to decide which e-cigarettes can stay on the market could force it to confront the menthol question much sooner.
The agency’s effort to decide which e-cigarettes can stay on the market could force it to confront the menthol question much sooner.
The agency’s effort to decide which e-cigarettes can stay on the market could force it to confront the menthol question much sooner.
E-cig manufacturers and anti-vaping groups alike are puzzled by the agency’s course so far.
E-cig manufacturers and anti-vaping groups alike are puzzled by the agency’s course so far.
E-cig manufacturers and anti-vaping groups alike are puzzled by the agency’s course so far.
E-cig manufacturers and anti-vaping groups alike are puzzled by the agency’s course so far.
E-cig manufacturers and anti-vaping groups alike are puzzled by the agency’s course so far.
The filing could clear the way for roughly 28 million children in the United States to be vaccinated against the virus, beginning in a matter of weeks.
The filing could clear the way for roughly 28 million children in the United States to be vaccinated against the virus, beginning in a matter of weeks.
The filing could clear the way for roughly 28 million children in the United States to be vaccinated against the virus, beginning in a matter of weeks.
The meetings set up a rough timeline for a slate of FDA decisions that could help the country avoid a damaging winter surge.
The meetings set up a rough timeline for a slate of FDA decisions that could help the country avoid a damaging winter surge.
The meetings set up a rough timeline for a slate of FDA decisions that could help the country avoid a damaging winter surge.
The meetings set up a rough timeline for a slate of FDA decisions that could help the country avoid a damaging winter surge.
Industry watchers predict many smaller operations keep will selling the products until the feds’ enforcement strategy is clearer.
The agency has deferred its decision on the largest vaping companies, including Juul.
The agency has deferred its decision on the largest vaping companies, including Juul.
The agency has deferred its decision on the largest vaping companies, including Juul.
The agency has deferred its decision on the largest vaping companies, including Juul.
The agency is reviewing millions of applications from e-cigarette makers, and must decide by Sept. 9 whether their products are “appropriate for the protection of public health.
The agency is reviewing millions of applications from e-cigarette makers, and must decide by Sept. 9 whether their products are “appropriate for the protection of public health.
The decision to greenlight Aduhelm has drawn widespread scrutiny, and came over the objections of independent advisers to the FDA and other experts who said there was little evidence of its effectiveness.
The decision to greenlight Aduhelm has drawn widespread scrutiny, and came over the objections of independent advisers to the FDA and other experts who said there was little evidence of its effectiveness.
The decision to greenlight Aduhelm has drawn widespread scrutiny, and came over the objections of independent advisers to the FDA and other experts who said there was little evidence of its effectiveness.
The FDA’s decision to approve the drug, siding with industry and patient advocates, raises new questions about whether it is lowering its burden of proof for drugmakers.
The FDA’s decision to approve the drug, siding with industry and patient advocates, raises new questions about whether it is lowering its burden of proof for drugmakers.